Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ironwood Pharmaceuticals's ROE % for the quarter that ended in Jun. 2026 was Negative Equity. Ironwood Pharmaceuticals's PB Ratio for the quarter that ended in Jun. 2026 was N/A.
Ironwood Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2026 was Negative Equity.
Ironwood Pharmaceuticals ROE % Adjusted to Book Value Related Terms
Ironwood Pharmaceuticals ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Ironwood Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ironwood Pharmaceuticals ROE % Adjusted to Book Value Chart
FRA:I76 vs TLRY, AQST, ELTP: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ironwood Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ironwood Pharmaceuticals ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ironwood Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Ironwood Pharmaceuticals's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of Negative Equity% mean?
Ironwood Pharmaceuticals (FRA:I76) has a ROE % Adjusted to Book Value of Negative Equity% as of Jun. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Ironwood Pharmaceuticals and its competitors.
Is Ironwood Pharmaceuticals' ROE % Adjusted to Book Value too high?
Ironwood Pharmaceuticals' current ROE % Adjusted to Book Value is Negative Equity%. Overall, Ironwood Pharmaceuticals has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ironwood Pharmaceuticals' ROE % Adjusted to Book Value compare to TLRY and AQST?
Ironwood Pharmaceuticals' ROE % Adjusted to Book Value of Negative Equity% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Ironwood Pharmaceuticals and its competitors. Ironwood Pharmaceuticals's current ROE % Adjusted to Book Value is Negative Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ironwood Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ironwood Pharmaceuticals (FRA:I76) is currently considered Fairly Valued. The stock's GF Value™ is €3.81, compared to a current price of €3.66 — trading 3.9% below its estimated fair value. The current ROE % Adjusted to Book Value is Negative Equity%. Ironwood Pharmaceuticals' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Ironwood Pharmaceuticals (FRA:I76), the current ROE % Adjusted to Book Value is Negative Equity% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ironwood Pharmaceuticals (FRA:I76) Overvalued in 2026?
Based on GuruFocus' analysis, Ironwood Pharmaceuticals stock appears to be undervalued.
The current stock price of €3.66 is trading 3.9% below its estimated GF Value™ of €3.81.
GuruFocus considers Ironwood Pharmaceuticals to be Fairly Valued.
Key valuation signals for FRA:I76:
ROE % Adjusted to Book Value: Negative Equity%
GF Value™: €3.81 vs. price of €3.66 (3.9% below fair value)
No single metric tells the full story. See the FRA:I76 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
65GF Score
Get the complete analysis for FRA:I76
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:I76 has been successfully added to your 
